“Today’s results build upon the decades of research CLINUVEL has conducted into the use of afamelanotide to protect skin from light, with the first evidence that a single dose of the drug has a photoprotective effect in healthy volunteers. These data add to our regulatory dossier for XP while further developing our specialised healthcare products for wider populations at highest risk of UV-induced damage and skin cancer,” Dr Bilbao said.
Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory...
The START-001 trial (NCT05592626) is currently enrolling patients at two top US cancer research institutes, National Institutes of Health (NIH)'s National Cancer Institute (NCI) and Mass General Hospital (MGH)/Harvard Medical School, co-led by seasoned clinical and translational researchers James Gulley, M.D., Ph.D., of NCI and Ryan Sullivan, M.D., of MGH. Additional top cancer centers are planned to join these clinical sites to support the further expansion of the study.
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
The strategic collaboration will integrate Solid Biosciences vector biology, manufacturing capabilities and drug development experience with Phlox’s deep expertise in genetic cardiomyopathies and RNA therapeutics. The companies will collaborate to develop novel precision genetic medicines for this form of DCM.
Poolbeg Pharma plc Identifies New Potential Drug Candidates for Respiratory Syncytial Virus infections As part of AI Programme
Poolberg Pharma has prioritized compounds with existing Phase I clinical data and which could, if successfully validated, be repositioned as novel treatments for RSV infection.
“The Nova XS team is constantly seeking opportunities to hear from people who’s lives have been impacted by the pain and suffering from the confusing process of needle drug delivery,” said Alina Su, the CEO and Co-Founder of Nova XS. “This webinar is our way of connecting with the chronic disease community and sharing with them ways they can help us on our mission to make drug delivery more accessible.”
Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting
NRTX-1001 administration was well-tolerated, with notable seizure reduction reported in early data from the first two patients in Phase I/II clinical trial